Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin

TERMINATED · PHASE2 · Lymphoma, Non-Hodgkin

The stopping rule was applied because of low response rates.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.